Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats

Clinics

Volumn 66, Issue 8, 2011, Pages 1457-1462

  Girardi, Jose Marcos ^a,b   Farias, Rogerio Estevan ^a   Ferreira, Ana Paula ^a   Raposo, Nadia Rezende Barbosa ^a,c  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

HMG CoA reductase inhibitors; Hypertension; Interleukins; Kidney; L NAME

Indexed keywords

EID: 80052707338     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000800025     Document Type: Article

References (43)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
2. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The Safety of Rosuvastatin as Used in Common Clinical Practice. A Postmarketing Analysis. Circulation. 2005;111:3051-7.
3. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508, doi: 10.1001/jama.297.5.499.
4. Suh JW, Choi DJ, Chang HJ, Cho YS, Youn TJ, and Chae IH, et al. HMGCo A reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. J Korean Med Sci. 2010;25:16-23, doi: 10.3346/jkms.2010.25.1.16.
5. Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. 2005;16(suppl):S11-S17, doi: 10.1681/ASN.2004110958.
6. Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocininduced diabetic rats. Eur J Pharm. 2007;568;242-247, doi: 10.1016/j.ejphar.2007.04.011.
7. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one more the other? Am J Hypertens. 1988;1:335-47.
8. Caetano ER, Zats R, Saldanha LB, Praxedes Jn. Hypertensive nephrosclerosis as a relevant cause of chronic renal failure. Hypertension. 2001;38:171-6.
9. Zats R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension. 1998;32:958-64.
10. Barbuto N, Almeida JR, Pereira LMM, Mandarim-de-Lacerda CA. Renal córtex remodeling in nitric oxide deficient rats treated with enalapril. J Cell Mol Med. 2004;8:102-8, doi: 10.1111/j.1582-4934.2004.tb00264.x.
11. Bae EH, Kim IJ, Park JW, Ma SK, Lee JU, Kim SW. Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats. Nephrol Dial Transplant. 2010;25:1051-9, doi: 10.1093/ndt/gfp604.
12. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59;260-9, doi: 10.1046/j.1523-1755.2001.00487.x
13. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998;31:225-31.
14. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterol-lowering effects. Kidney Int. 2000;58:1420-30, doi: 10.1046/j.1523-1755.2000.00304.x.
15. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension. 2004;44:186-90.
16. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol. 2004;286:46-57, doi: 10.1152/ajprenal.00428.2002.
17. Mauro Vieira J Jr, Mantovani E, Tavares Rodrigues L, Delle H, Noronha IL, Fujihara CK, et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant. 2005;20:1582-91, doi: 10.1093/ndt/ gfh859.
18. Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension, Am J Hypertens. 2005;18:1496-502.
19. Ribeiro MO, Antunes E, Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension, Hypertension. 1992;20:298-303.
20. Rossi MA, Colombini-Netto M. Chronic inhibition of NO synthesis per se promotes structural intimal remodeling of the rat aorta. J Hypert. 2001;19:1567-79, doi: 10.1097/00004872-200109000-00008.
21. Jover B, Mimran A. Nitric oxide inhibition and renal alterations. J Cardiovasc Pharmacol. 2001;38:65-70, doi: 10.1097/00005344-200111002-00016.
22. Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, Kuroda M. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta. 1995;1254:7-12.
23. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol. 2003;42:1091-7, doi: 10.1016/S0735-1097(03)00926-4.
24. Green LC, Wagner DA, Glogwski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem. 1982;126:131-8, doi: 10.1016/0003-2697(82)90118-X.
25. Tu X, Chen X, Xie Y, Shi S, Wang J, Chen Y, Li J. Anti-inflammatory Renoprotective Effect of Clopidogrel and Irbesartan in Chronic Renal Injury. J Am Soc Nephrol. 2008;19:77-83, doi: 10.1681/ASN.2007020160.
26. Hartner A, Veelken R, Wittmann M, Cordasic N. Effects os diabetes and hypertension on macrophage infiltration and matrix expansion in the rat kidney. BMC Nephrology. 2005;6:6, doi: 10.1186/1471-2369-6-6.
27. Pomaro D, Fonseca FAH, Ebihara Fet al. 2006. Quinapril promotes renal protection independently of glucose serum levels in hypercholesterolemic and diabetic rabbits. Int J Atheroscler. 2006;1:156-61.
28. Paulis L, Zicha J, Kunes J, Hojna S, Behuliak M, Celec P, et al. Regression of L-NAME-induced hypertension: the role of nitric oxide and endothelium-derived constricting factor. Hypertens Res. 2008;31:793-803, doi: 10.1291/hypres.31.793.
29. Morán A, Urbina AVO, Martín ML, Rodríguez-Barbero A, Román LS. Characterization of the contractile 5-hydroxytryptamine receptor in the autoperfused kidney of L-NAME hypertensive rats. Eur J Pharmacol. 2009;620:90-6, doi: 10.1016/j.ejphar.2009.08.026.
30. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc. Research. 2005;66:462-71, doi: 10.1016/j.cardiores.2005.02.008.
31. Zhai Y, Gao X, Wu Q. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol. 2008;587:196-203, doi: 10.1016/j.ejphar.2008.03.006.
32. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension. 2002;40:142-47, doi: 10.1161/01.HYP.0000024348.87637.6F.
33. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. JUPITER Study Group. N Engl J Med. 2008;359:2195-207, doi: 10.1056/NEJMoa0807646.
34. Navarro JF, Mora-Fernandez C. The role of TNF-a in diabetic nephropathy: Pathogenic and therapeutic implications Cytokine & Growth Factor Reviews. 2006;17:441-50.
35. Bourraindeloup M, Christophe A, Candiani G, Calleret M, Bourin MC, Badoual T, et al. N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-a Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats. Circulation. 2004;110:2003-9, doi: 10.1161/01.CIR.0000143630.14515.7C.
36. Dalla Vestra M, Mussap M, Gallina P, Bruseghin M, Cernigoi A, Saller A, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol. 2005;16(Suppl 1): S78-82, doi: 10.1681/ASN.2004110961.
37. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspect of interleukin 6. Immunol Today. 1990;11:443-9, doi: 10.1016/0167-5699(90)90173-7.
38. Dela Paz NG, Simeonidis S, Leo C, Rose DW, Collins T. Regulation of NF-κB-dependent gene expression by the POU domain transcription factor Oct-1. J Biol Chem. 2007;282:8424-34, doi: 10.1074/jbc.M606923200.
39. Baud L, Ardaillou R. Tumor necrosis factor in renal injury. Miner Electrolyte Metab. 1995;21:336-41.
40. Vieira Jr. JM, Rodrigues LT, Mantovani E, Dellê H, Mattar AL, Malheiros DMACet al. Statin Monotherapy Attenuates Renal Injury in a Salt-Sensitive Hypertension Model of Renal Disease. Nephron Physiol. 2005;101:82-91, doi: 10.1159/000087576.
41. Pereira LMM, Almeida JR, Mandarim-de-Lacerda CA. Kidney adaptation in nitric oxide-deficient Wistar and spontaneously hypertensive rats. Life Sciences. 2004;74:1375-86, doi: 10.1016/j.lfs.2003.08.015.
42. Lecian D, Demova H, Lodererova A, Zdychova J, Kluckova H, Teplan V, et al. Renal effects of HMG-CoA Reductase Inhibition in a rat modelo f chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res. 2006;29:135-43, doi: 10.1159/000094988.
43. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, Sanchez-Lopez E, Rodriguez-Vita J, Esteban V, et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension. 2007;50:377-83, doi: 10.1161/ HYPERTENSIONAHA.107.091264.